Active substances
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ANORO ELLIPTA | 62.5,25 µg,µg | Inhalation powder, pre-dispensed · Inhalation use | 1 Inhaler | SAR 158.40 | NCE · Prescription | GLAXO SAUDI ARABIA | Valid |
| ANORO ELLIPTA inhalation powder, pre-dispensed | 25, 62.5 µg | Inhalation powder, pre-dispensed · Inhalation use | 1 Inhaler | SAR 158.40 | NCE · Prescription | GLAXO OPERATION | Withdrawn by MAH · Not Marketed |
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Laventair Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ANORO ELLIPTA | 02418401 | 25 MCG / ACT; 62.5 MCG / ACT | POWDER · INHALATION | GLAXOSMITHKLINE INC |
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Umeclidinium bromide 65micrograms/dose / Vilanterol 22micrograms/dose dry powder inhaler | £32.50 | 30 dose | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.